Last reviewed · How we verify
TKM-080301
At a glance
| Generic name | TKM-080301 |
|---|---|
| Also known as | PLK1-HCC, PLK1 SNALP, TKM-PLK1 |
| Sponsor | Arbutus Biopharma Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients (PHASE1, PHASE2)
- Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma (PHASE1, PHASE2)
- TKM 080301 for Primary or Secondary Liver Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TKM-080301 CI brief — competitive landscape report
- TKM-080301 updates RSS · CI watch RSS
- Arbutus Biopharma Corporation portfolio CI